Literature DB >> 28925330

Preoperative Positron Emission Tomography for Node-Positive Head and Neck Cutaneous Squamous Cell Carcinoma.

Nir Hirshoren1, Elizabeth Olayos1, Alan Herschtal1, Aravind S Ravi Kumar2, David E Gyorki1,3.   

Abstract

Objectives Surgery is the primary treatment modality for node-positive cutaneous squamous cell carcinoma of the head and neck with no distant disease (HNcSCC-M0). The role of preoperative positron emission tomography/computed tomography (PET/CT) scan for these patients is unclear. We compared preoperative PET/CT with final histopathology among patients undergoing lymphadenectomy and/or parotidectomy for HNcSCC-M0. Study Design Case series with chart review. Setting Single Australian center. Subjects and Methods Investigation included disease parameters and preoperative CT and PET/CT findings of 64 patients with node-positive HNcSCC without distant metastatic disease. Fisher's exact test was used to test for a difference in the proportion of patients with chronic lymphocytic leukemia between the false- and true-negative PET/CT subgroups. Results Of 64 patients who underwent PET/CT prior to surgery for node-positive HNcSCC-M0, 56 underwent a neck dissection and 30, a parotidectomy. Of these, 13 neck dissections and 2 parotidectomies were performed in the absence of FDG-avid (18F-fludeoxyglucose) nodes in these nodal fields. The PET/CT positive predictive value of the neck was 91.1%. The negative predictive values in the neck and parotid regions were 60%. Of the false-negative subgroup, 66.7% had chronic lymphocytic leukemia, compared with 11.1% of the true-negative subgroup ( P = .09). Based on PET/CT findings, surgical plans according to preoperative CT were changed for 6.25% of patients. Conclusion Use of PET/CT for surgical candidates with node-positive HNcSCC-M0 has high specificity and positive predictive value with relatively low sensitivity and negative predictive value. A statistical trend toward a higher rate of chronic lymphocytic leukemia among patients with false-negative results is suggested.

Entities:  

Keywords:  PET/CT scan; accuracy analysis; chronic lymphocytic leukemia; cutaneous squamous cell carcinoma; radiology

Mesh:

Year:  2017        PMID: 28925330     DOI: 10.1177/0194599817731735

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  4 in total

1.  Restaging [18F] fludeoxyglucose positron emission tomography/computed tomography scan in recurrent cutaneous squamous cell carcinoma: Diagnostic performance and prognostic significance.

Authors:  Sonia Mahajan; Christopher A Barker; Audrey Mauguen; Bhuvanesh Singh; Neeta Pandit-Taskar
Journal:  J Am Acad Dermatol       Date:  2019-09-25       Impact factor: 11.527

2.  A Novel Radiotherapeutic Approach to Treat Bulky Metastases Even From Cutaneous Squamous Cell Carcinoma: Its Rationale and a Look at the Reliability of the Linear-Quadratic Model to Explain Its Radiobiological Effects.

Authors:  Gianluca Ferini; Paolo Castorina; Vito Valenti; Salvatore Ivan Illari; Ilias Sachpazidis; Luigi Castorina; Maurizio Marrale; Stefano Pergolizzi
Journal:  Front Oncol       Date:  2022-02-23       Impact factor: 6.244

Review 3.  Cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia: a systematic review of the literature.

Authors:  Michela Lai; Riccardo Pampena; Luigi Cornacchia; Giulia Odorici; Alfredo Piccerillo; Giovanni Pellacani; Ketty Peris; Caterina Longo
Journal:  Int J Dermatol       Date:  2021-08-05       Impact factor: 3.204

4.  Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [18F]FDG PET/CT and MRI.

Authors:  Christian Linz; Roman C Brands; Olivia Kertels; Alexander Dierks; Joachim Brumberg; Elena Gerhard-Hartmann; Stefan Hartmann; Andreas Schirbel; Sebastian Serfling; Yingjun Zhi; Andreas K Buck; Alexander Kübler; Julian Hohm; Constantin Lapa; Malte Kircher
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05-29       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.